This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Sep 11;376(9744):847-9.

doi: 10.1016/S0140-6736(10)61314-1.

Ivabradine in heart failure--no paradigm SHIFT…yet

John R Teerlink¹

Affiliations

PMID: 20801501
DOI: 10.1016/S0140-6736(10)61314-1

Comment

Ivabradine in heart failure--no paradigm SHIFT…yet

John R Teerlink. Lancet. 2010.

. 2010 Sep 11;376(9744):847-9.

doi: 10.1016/S0140-6736(10)61314-1.

Author

John R Teerlink¹

Affiliation

¹ School of Medicine, University of California, San Francisco, San Francisco, CA, USA. john.teerlink@ucsf.edu

PMID: 20801501
DOI: 10.1016/S0140-6736(10)61314-1

No abstract available

PubMed Disclaimer

Comment on

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Böhm M, et al. Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7. Lancet. 2010. PMID: 20801495 Clinical Trial.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Swedberg K, et al. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Lancet. 2010. PMID: 20801500 Clinical Trial.

Similar articles

SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
[No authors listed] [No authors listed] Cardiovasc J Afr. 2012 Jul;23(6):360. Cardiovasc J Afr. 2012. PMID: 23961539 No abstract available.
Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D, Savarese G, Dahlström U, Fu M, Howlett J, Ezekowitz JA, Lund LH. Das D, et al. Circ Heart Fail. 2017 Sep;10(9):e004112. doi: 10.1161/CIRCHEARTFAILURE.117.004112. Circ Heart Fail. 2017. PMID: 28903983
Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, Böhm M, Depre C, Wu Y, Maya J, Dominjon F. Borer JS, et al. Cardiology. 2017;136(2):138-144. doi: 10.1159/000449243. Epub 2016 Sep 10. Cardiology. 2017. PMID: 27614723 Clinical Trial.
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS, Deedwania PC, Kim JB, Böhm M. Borer JS, et al. Am J Cardiol. 2016 Dec 15;118(12):1948-1953. doi: 10.1016/j.amjcard.2016.08.089. Epub 2016 Sep 15. Am J Cardiol. 2016. PMID: 27780557 Review.
Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Weeda ER, Nguyen E, White CM. Weeda ER, et al. Ann Pharmacother. 2016 Jun;50(6):475-85. doi: 10.1177/1060028016631571. Epub 2016 Feb 25. Ann Pharmacother. 2016. PMID: 26917820 Review.

See all similar articles

Cited by

Association between systolic ejection time and outcomes in heart failure by ejection fraction.
Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, Honarpour N, Velazquez EJ. Patel PA, et al. Eur J Heart Fail. 2020 Jul;22(7):1174-1182. doi: 10.1002/ejhf.1659. Epub 2019 Dec 21. Eur J Heart Fail. 2020. PMID: 31863532 Free PMC article.
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.
Rushworth GF, Lambrakis P, Leslie SJ. Rushworth GF, et al. Ther Adv Drug Saf. 2011 Feb;2(1):19-28. doi: 10.1177/2042098610393209. Ther Adv Drug Saf. 2011. PMID: 25083199 Free PMC article. Review.
Molecular and functional evidence of HCN4 and caveolin-3 interaction during cardiomyocyte differentiation from human embryonic stem cells.
Bosman A, Sartiani L, Spinelli V, Del Lungo M, Stillitano F, Nosi D, Mugelli A, Cerbai E, Jaconi M. Bosman A, et al. Stem Cells Dev. 2013 Jun 1;22(11):1717-27. doi: 10.1089/scd.2012.0247. Epub 2013 Feb 27. Stem Cells Dev. 2013. PMID: 23311301 Free PMC article.
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm.
Loudon BL, Noordali H, Gollop ND, Frenneaux MP, Madhani M. Loudon BL, et al. Br J Pharmacol. 2016 Jun;173(12):1911-24. doi: 10.1111/bph.13480. Epub 2016 May 6. Br J Pharmacol. 2016. PMID: 26993743 Free PMC article. Review.
HCN channels in the heart: lessons from mouse mutants.
Herrmann S, Hofmann F, Stieber J, Ludwig A. Herrmann S, et al. Br J Pharmacol. 2012 May;166(2):501-9. doi: 10.1111/j.1476-5381.2011.01798.x. Br J Pharmacol. 2012. PMID: 22141457 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science